Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01552447 · ClinicalTrials.gov registry record · NA

Human Amniotic Membrane Grafting and Standard of Care Versus Standard of Care Alone in the Treatment of Venous Leg Ulcers

A NA study of Venous Leg Ulcer, sponsored by MiMedx Group.

Completed
Registry status
NA
Development phase
98
Enrollment target
5
Study locations

NCT01552447 is a NA study of Venous Leg Ulcer that has completed, run by MiMedx Group. The registered enrollment target is 98 participants, below the 242-participant average among 35 other Venous Leg Ulcer trials with a reported enrollment target (60% lower). The trial reports 5 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01552447, a NA study of Venous Leg Ulcer, has completed, sponsored by MiMedx Group.

COMPLETED
Registry status
NA
Development phase
98 participants
Enrollment target
5
Study locations

Study Summary

The purpose of this study is to determine whether the EpiFix human amniotic membrane is effective in the treatment of venous leg ulcers.

Conditions Studied

Interventions

  • OTHER EpiFix
  • OTHER Compression Therapy

Study Locations (5)

Pennsylvania

  • St. Vincent's Health Center - Erie
  • Armstrong County Memorial Hospital - Kittanning

Florida

  • Eric J. Lullove DPM - Boca Raton

Massachusetts

  • MetroWest Medical Center - Framingham

Oklahoma

  • St. Johns Wound Center - Tulsa

Trial Details

FieldValue
Enrollment Target 98 participants
Start Date 2012-03
Est. Completion 2014-05
Phase NA

Sponsor

MiMedx Group

32 total trials

What the Registry Record Tells You About NCT01552447

The ClinicalTrials.gov registry entry for NCT01552447 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 98 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 242-participant average among 35 other Venous Leg Ulcer trials with a reported enrollment target (60% lower). The listed sponsor is MiMedx Group, which has 32 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Venous Leg Ulcer appearing as the primary indexed condition, and to 2 interventions - of which EpiFix is the first listed.

NCT01552447 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Pennsylvania, Florida, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT01552447 about?

NCT01552447 is a clinical study titled "Human Amniotic Membrane Grafting and Standard of Care Versus Standard of Care Alone in the Treatment of Venous Leg Ulcers". The purpose of this study is to determine whether the EpiFix human amniotic membrane is effective in the treatment of venous leg ulcers.

What is the current status of trial NCT01552447?

This trial is currently completed. It is a NA study. The enrollment target is 98 participants. The study started on 2012-03. Estimated completion is 2014-05.

What conditions does trial NCT01552447 study?

This clinical trial studies the following conditions: Venous Leg Ulcer.

What interventions are being tested in trial NCT01552447?

The interventions under investigation include: EpiFix (OTHER), Compression Therapy (OTHER).

Who is sponsoring clinical trial NCT01552447?

This trial is sponsored by MiMedx Group, which has 32 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01552447 being conducted?

This trial has 5 study locations across Florida, Massachusetts, Oklahoma, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Venous Leg Ulcer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.